Format

Send to

Choose Destination
Rev Med Inst Mex Seguro Soc. 2017 Sep-Oct;55(5):654-659.

[Case series of Clostridium difficile NAP1/027/BI with novels treatments].

[Article in Spanish; Abstract available in Spanish from the publisher]

Author information

1
Departamento de Medicina Interna, Hospital Christus Muguerza Alta Especialidad, Monterrey, Nuevo León, México silvia_pt_72@hotmail.com.

Abstract

in English, Spanish

BACKGROUND:

Clostridium difficile is a spore-forming bacterium, producing exotoxins, causing potentially fatal nosocomial diarrhea. They have recently reported outbreaks of C. difficile ribotype 027, which is characterized by a hypervirulent strain and high resistance to standard therapy.

CLINICAL CASE:

We present three cases of Clostridium difficile NAP1/027/BI associated infection, they were presented with different clinical manifestations. Two of the patients were successfully treated with the combination of vancomycin plus tigecycline. The other case was treated with fecal microbiota transplant, with resolution of the disease.

CONCLUSION:

in patients with Clostridium difficile NAP1/027/BI associated infection is a good therapeutic option to consider the use of tigecycline in conjunction with vancomycin, as well as fecal microbiota transplantation.

KEYWORDS:

Clostridium difficile; Entrocolitis, pseudomembranous; Fecal microbiota transplantation

PMID:
29193949
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center